Life Science Investor Mandates
(Aug. 2 - Aug. 8
)
|
|
|
|
|
Invests in Early-Stage Therapeutics and Digital Health Solutions of Strategic Fit
|
|
Invests Up to $19M in Medical Device and Diagnostic Companies in Cardiovascular, Metabolic Diseases, etc.
|
|
Seeks to Partner with Early-Stage Therapeutic Opportunities in Oncology, CNS, Rare Disease, Pain Management, etc.
|
|
Invests Globally in Tech-Based Diagnostic & Digital Health Companies, Especially Those Seeking China Market Entry
|
|
|
 |
 |
By
Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series
 The Redefining Early Stage Investments (RESI) conference series consists of investors (the buyers) and the life science startups (the sellers), and the service providers who have the services that the startup companies need to move their products towards commercialization. Service provider sales and business development staff have a tremendous opportunity to use RESI to keep their business pipelines full, as a good portion of the capital raised after an investment transaction often goes to 3rd party service providers. LSN and RESI act as a hub for the early-stage life science ecosystem, bringing all of the players together to interact and form relationships. Indeed, It is a twofold proposition for the service providers who attend RESI: first, they have an opportunity to meet the startup firms that would benefit from their services. Second, they have the chance to meet the investors that attend RESI, who are not only funding these new prospective clients but also have a portfolio of funded firms that may be in need of 3rd party services. A lot of the big global CROs that regularly attend RESI love the fact that creating relationships with the funding source can help drive ongoing strategic relationships.
The BD staff of the service providers can also take advantage of the RESI format - having a partnering conference every few months across North America allows them to regularly schedule a full day of meetings with prospective new clients and potentially closing a lot of new deals...
|
|
|
|
 In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines. This RESI Boston panel will feature five speakers and a moderator from various big pharma companies discussing topics such as:
- How big pharma sources assets
- The evaluation and investment process
- Key factors of interest
- How early-stage big pharma is willing to look
At RESI Boston on September 6th, we welcome five speakers from major pharma firms who will explain how they evaluate early stage companies for potential licensing and partnership relationships. The panelists are:
- Alex Rabiee, Director, Business Development, Amgen
- Lizabeth Leveille, Head, Boston Innovation Hub, Merck
- Imran Nasrullah, Director, BD&L, Strategic Partnering, Boehringer Ingelheim
- Niels Emmerich, Senior Director, Global Head Search & Evaluation Oncology, AbbVie
- Tim Luker, VP External Innovation, Eli Lilly
|
|
|
|
By Nono Hu, Director of Marketing, LSN
 If investors find interest in your slide deck and executive summary, what is the next thing they typically do? They look you up on the internet. A fundraising entrepreneur would not want to miss out on this opportunity to connect with interested investors. As a key component of your branding and messaging strategy, a good website provides a fully integrated and interactive package of information about your story, technology, team, and most recent updates. In this week's edition of summer reading series, we will explore the issues a life science executive must consider when creating a strong web presence.
Chapter 7 of The Life Science Executive's Fundraising Manifesto "Establishing a Web Presence," discusses what makes a simple and effective website, whether to do it yourself or hire a web designer, how to employ search engine optimization to drive traffic to your site, and the importance of constantly managing and updating your content.
Over the past few weeks, we have laid the groundwork for a marketing campaign. Join us next week as we go outbound in Chapter 8, "
Leveraging Cloud Infrastructure to Manage an Outbound Campaign," where we identify useful tools for managing your outbound activities.
|
 |
|
|
Created & Produced by
|
 |
|
|
|
